Clinical Research Directory

Inclusion Criteria: * Gastric or gastroesophageal junction adenocarcinoma confirmed by pathology or cytology; * Resectable or potentially resectable gastric cancer with clinical stage of cT3-4aN + M0 or cT4bNxM0; * Patients who are not allowed to receive previous anti-tumor therapy including chemotherapy radiotherapy immunotherapy or targeted therapy; Adequate organ function defined as follows: hematological ANC ≥ 1.5 \* 10 \^ 9/L hemoglobin ≥ 9 g/dL platelets ≥ 80 \* 10 \^ 9/L albumin ≥ 30 g/L serum bilirubin ≤ 1.5 × ULN AST and ALT ≤ 2.5 × ULN ALP ≤ 2.5 × ULN TBIL ≤ 1.5 × ULN renal serum creatinine \< 1.5 × ULN. * KPS ≥ 70 points; * 18-75 years old male or female; * Subjects voluntarily signed a written informed consent form. Exclusion Criteria: * Associated with distant metastasis; * Patients with known hypersensitivity or metabolic disorder to fluorouracil or oxaliplatin or known hypersensitivity or intolerance to the study drug; Patients with primary malignant tumors at other sites. Subjects who were disease-free for 5 years or had a history of completely resected non-melanoma skin cancer or successfully treated carcinoma in situ were eligible; * Gastrointestinal emergencies include: inability to swallow (complete or incomplete) gastrointestinal obstruction gastrointestinal bleeding and gastrointestinal perforation; * Patients who are pregnant have neurological diseases or mental illness and mental and language disorders; * Known uncontrolled angina pectoris arrhythmia congestive heart failure or myocardial infarction or a history of cardiac insufficiency within 6 months prior to study enrollment; * Any concurrent disease or condition that may make the subject unsuitable for study participation or any serious medical condition that may interfere with the subject 's safety; * Persons who are incapable (legally) or unsuitable for continuing study treatment for ethical/medical reasons.